ProShare Advisors’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $278K | Sell |
66,749
-577
| -0.9% | -$2.19K | ﹤0.01% | 1470 |
|
|
2026
Q1 | $236K | Sell |
67,326
-6,407
| -9% | -$20.5K | ﹤0.01% | 1475 |
|
|
2025
Q4 | $201K | Buy |
73,733
+16,194
| +28% | +$37.5K | ﹤0.01% | 1718 |
|
|
2025
Q3 | $125K | Sell |
57,539
-7,502
| -12% | -$17.7K | ﹤0.01% | 1801 |
|
|
2025
Q2 | $112K | Sell |
65,041
-9,199
| -12% | -$22.9K | ﹤0.01% | 1858 |
|
|
2025
Q1 | $247K | Sell |
74,240
-17,535
| -19% | -$90.4K | ﹤0.01% | 1546 |
|
|
2024
Q4 | $679K | Buy |
91,775
+25,996
| +40% | +$241K | ﹤0.01% | 1094 |
|
|
2024
Q3 | $618K | Buy |
65,779
+16,718
| +34% | +$158K | ﹤0.01% | 1015 |
|
|
2024
Q2 | $393K | Sell |
49,061
-13,149
| -21% | -$141K | ﹤0.01% | 1114 |
|
|
2024
Q1 | $922K | Buy |
62,210
+7,891
| +15% | +$91.8K | ﹤0.01% | 812 |
|
|
2023
Q4 | $442K | Buy |
54,319
+8,325
| +18% | +$43.6K | ﹤0.01% | 1111 |
|
|
2023
Q3 | $209K | Buy |
45,994
+4,415
| +11% | +$28.8K | ﹤0.01% | 1438 |
|
|
2023
Q2 | $293K | Buy |
41,579
+8,287
| +25% | +$59.3K | ﹤0.01% | 1290 |
|
|
2023
Q1 | $203K | Buy |
33,292
+836
| +3% | +$5.77K | ﹤0.01% | 1439 |
|
|
2022
Q4 | $207K | Buy |
32,456
+2,547
| +9% | +$19.9K | ﹤0.01% | 1469 |
|
|
2022
Q3 | $287K | Buy |
29,909
+731
| +3% | +$8.43K | ﹤0.01% | 1175 |
|
|
2022
Q2 | $322K | Buy |
29,178
+12,933
| +80% | +$169K | ﹤0.01% | 1172 |
|
|
2022
Q1 | $270K | Sell |
16,245
-5,851
| -26% | -$90.5K | ﹤0.01% | 1698 |
|
|
2021
Q4 | $422K | Sell |
22,096
-11,024
| -33% | -$243K | ﹤0.01% | 1570 |
|
|
2021
Q3 | $817K | Buy |
33,120
+5,657
| +21% | +$133K | ﹤0.01% | 975 |
|
|
2021
Q2 | $715K | Buy |
27,463
+7,125
| +35% | +$185K | ﹤0.01% | 1259 |
|
|
2021
Q1 | $644K | Sell |
20,338
-2,299
| -10% | -$95.3K | ﹤0.01% | 1281 |
|
|
2020
Q4 | $1.05M | Sell |
22,637
-962
| -4% | -$38.2K | ﹤0.01% | 861 |
|
|
2020
Q3 | $777K | Buy |
23,599
+623
| +3% | +$19.1K | ﹤0.01% | 792 |
|
|
2020
Q2 | $631K | Sell |
22,976
-1,232
| -5% | -$40.5K | ﹤0.01% | 853 |
|
|
2020
Q1 | $725K | Sell |
24,208
-18,965
| -44% | -$503K | 0.01% | 660 |
|
|
2019
Q4 | $1.2M | Sell |
43,173
-3,410
| -7% | -$77.6K | 0.01% | 743 |
|
|
2019
Q3 | $848K | Sell |
46,583
-683
| -1% | -$15.1K | ﹤0.01% | 806 |
|
|
2019
Q2 | $1.16M | Sell |
47,266
-6,172
| -12% | -$93K | 0.01% | 712 |
|
|
2019
Q1 | $508K | Buy |
53,438
+564
| +1% | +$5.48K | ﹤0.01% | 1011 |
|
|
2018
Q4 | $468K | Buy |
52,874
+3,841
| +8% | +$37K | ﹤0.01% | 975 |
|
|
2018
Q3 | $552K | Buy |
49,033
+536
| +1% | +$7.61K | ﹤0.01% | 1061 |
|
|
2018
Q2 | $621K | Sell |
48,497
-1,443
| -3% | -$21.1K | ﹤0.01% | 1018 |
|
|
2018
Q1 | $844K | Buy |
49,940
+1,671
| +3% | +$25.3K | 0.01% | 896 |
|
|
2017
Q4 | $386K | Buy |
48,269
+9,329
| +24% | +$74.9K | ﹤0.01% | 1258 |
|
|
2017
Q3 | $302K | Buy |
38,940
+2,266
| +6% | +$14.3K | ﹤0.01% | 1134 |
|
|
2017
Q2 | $270K | Sell |
36,674
-3,023
| -8% | -$19.2K | ﹤0.01% | 1220 |
|
|
2017
Q1 | $296K | Sell |
39,697
-10,386
| -21% | -$76.1K | ﹤0.01% | 1251 |
|
|
2016
Q4 | $348K | Buy |
50,083
+7,928
| +19% | +$54.6K | ﹤0.01% | 1271 |
|
|
2016
Q3 | $347K | Buy |
42,155
+434
| +1% | +$3.67K | ﹤0.01% | 1095 |
|
|
2016
Q2 | $338K | Buy |
41,721
+1,064
| +3% | +$6.68K | ﹤0.01% | 1152 |
|
|
2016
Q1 | $207K | Sell |
40,657
-4,365
| -10% | -$23.9K | ﹤0.01% | 1401 |
|
|
2015
Q4 | $348K | Buy |
+45,022
| New | +$312K | ﹤0.01% | 1224 |
|
Other funds holding IOVA
MFM
PAI
ProShare Advisors's IOVA Position: Q2 2026 in Review
ProShare Advisors reduced its Iovance Biotherapeutics (IOVA) stake by 0.86% in Q2 2026, selling an estimated $2.19K and leaving 66,749 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #1470.
ProShare Advisors first reported a position in IOVA in Q4 2015 and has held it in 43 quarters since. The position peaked at $1.2M in Q4 2019. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.
- ProShare Advisors held 66,749 shares of Iovance Biotherapeutics worth $278K as of Q2 2026.
- ProShare Advisors sold 577 Iovance Biotherapeutics shares in Q2 2026, an estimated $2.19K.
- Iovance Biotherapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1470 holding.
- ProShare Advisors first reported a position in Iovance Biotherapeutics in Q4 2015 and has held it in 43 quarters since.
- ProShare Advisors's Iovance Biotherapeutics position peaked at $1.2M in Q4 2019.
- 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.